Aptamers for use in the treatment of coronaviridae infections
AssigneeBerlin Cures GmbH
InventorsAnnekathrin Haberland, Johannes Müller, Gerd Wallukat, Peter Göttel
Life of this patent
Estimating the term…
Abstract
The present invention relates to new aptamer molecules for use in treating, curing or preventing disease symptoms associated with long COVID in a patient having overcome an infection with a virus from the Coronaviridae family, a pharmaceutical composition and a kit comprising such aptamer molecules.
Claims14
A method of treating long COVID in a subject having overcome an infection with a virus from the Coronaviridae family, comprising administering to a subject in need thereof an effective amount of an aptamer comprising a nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No. 1.
A pharmaceutical composition comprising at least one pharmaceutically acceptable excipient and an effective amount of an aptamer comprising a nucleic acid sequence of SEQ ID No. 1 (GGT TGG TGT GGT TGG) and/or a nucleic acid sequence being at least 80% identical to SEQ ID No. 1.
Dependencies are inferred from the claim text.